



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

StockExchange-NSE letters/MM:637

August 26, 2016

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on June 30, 2016.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on June 30, 2016 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 11.45 a.m. and concluded at 12.55 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

(Rs.in lakhs)

Sl.No.	Particulars	Quarter ended	
		30-06-2016	30-06-2015
		Unaudited	Unaudited
1	Income from Operations		
	a. Net sales (Net of excise duty)	30,078.68	27,914.93
	b. Other Operating Income	843.87	505.92
	Total Income from Operations (Net) (a+b)	30,922.55	28,420.85
2	Expenses		
	a. Cost of materials consumed	9,555.32	9,022.98
	b. Purchases of stock-in-trade	2,135.01	2,309.10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(174.06)	599.54
	d. Employees benefits expense	4,620.50	4,058.37
	e. Depreciation and amortization expense	1,131.66	977.00
	f. Exchange Fluctuation Transactional (Gain)/Loss	(3.27)	118.72
	g. Other Expenses	7,739.16	7,322.46
	Total Expenses	25,004.32	24,408.17
3	Profit from Operations before Other Income, Finance Cost (1-2)	5,918.23	4,012.68
4	Other Income	1,096.72	1,103.16
5	Profit before Finance Cost (3+4)	7,014.95	5,115.84
6	Finance Cost	77.88	197.83
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,937.07	4,918.01
8	Exchange Fluctuation Translation Gain / (Loss)	(128.74)	406.66
9	Profit before Tax (7-/+8)	6,808.33	5,324.67
10	Tax expenses	1,822.82	1,360.89
11	Net Profit/(Loss) after Tax (9-10)	4,985.51	3,963.78
12	Other Comprehensive Income (net of Tax)	(8.07)	(7.74)
13	Total Comprehensive Income after Tax (11+12)	4,977.44	3,956.04
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.16
15	(I) Earning per share(EPS) (of Rs. 2/- each not annualised)		
	(1) Basic	5.88	4.67
	(2) Diluted	5.88	4.67

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 26, 2016.
- The financial results for the quarter ended June 2016 and June 2015 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016.
- The auditors have carried out limited review of the above results for the quarter ended June 2016. Ind As compliant financial results for the quarter ended June 2015 have not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results for the said quarter provide a true and fair view of the affairs of the Company.

[Signature]

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380


- 4 The reconciliation between net profit for the quarter ended June 2015 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

	(Rs. in lakhs)
Net profit reported for June 2015 as per previous Indian GAAP	3,428.19
Add/(Less) : Adjustments	
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.84
Net gain arising on fair valuation of Investments	657.89
Net gain arising on fair valuation of Forward Contracts	8.02
Others	13.73
Deferred Tax Impact on above Adjustments	(155.89)
Net Profit after Tax as per Ind AS	3,963.78

- 5 The Company has one reportable segment viz. Pharmaceuticals.
6 The figures for the previous period have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : August 26, 2016


J.B. Mody
Chairman & Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To
The Board of Directors of
J. B. CHEMICALS & PHARMACEUTICALS LIMITED


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of J. B. Chemicals & Pharmaceuticals Limited ("the Company"), for the quarter ended 30th June, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016. This statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016, including the manner in which it is to be disclosed, or it contains any material misstatement.

We have not reviewed the standalone unaudited financial results and other financial information for the quarter ended 30th June, 2015 which have been presented solely based on the financial information compiled by the Management.

For J. K. Shah & Co
Chartered Accountants
Firm Registration No. 109606W



J.K. Shah
Partner
Membership No. 03662



Place: Mumbai
Date: 26th August, 2016



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

(Rs.in lakhs)

Sl.No.	Particulars	Quarter ended	
		30-06-2016	30-06-2015
		Unaudited	Unaudited
1	Income from Operations		
	a. Net sales (Net of excise duty)	30,078.68	27,914.93
	b. Other Operating Income	843.87	505.92
	Total Income from Operations (Net) (a+b)	30,922.55	28,420.85
2	Expenses		
	a. Cost of materials consumed	9,555.32	9,022.98
	b. Purchases of stock-in-trade	2,135.01	2,309.10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(174.06)	599.54
	d. Employees benefits expense	4,620.50	4,058.37
	e. Depreciation and amortization expense	1,131.66	977.00
	f. Exchange Fluctuation Transactional (Gain)/Loss	(3.27)	118.72
	g. Other Expenses	7,739.16	7,322.46
	Total Expenses	25,004.32	24,408.17
3	Profit from Operations before Other Income, Finance Cost (1-2)	5,918.23	4,012.68
4	Other Income	1,096.72	1,103.16
5	Profit before Finance Cost (3+4)	7,014.95	5,115.84
6	Finance Cost	77.88	197.83
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,937.07	4,918.01
8	Exchange Fluctuation Translation Gain / (Loss)	(128.74)	406.66
9	Profit before Tax (7-/+8)	6,808.33	5,324.67
10	Tax expenses	1,822.82	1,360.89
11	Net Profit/(Loss) after Tax (9-10)	4,985.51	3,963.78
12	Other Comprehensive Income (net of Tax)	(8.07)	(7.74)
13	Total Comprehensive Income after Tax (11+12)	4,977.44	3,956.04
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.16
15	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)		
	(1) Basic	5.88	4.67
	(2) Diluted	5.88	4.67

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 26, 2016.
- The financial results for the quarter ended June 2016 and June 2015 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016.
- The auditors have carried out limited review of the above results for the quarter ended June 2016. The compliant financial results for the quarter ended June 2015 have not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results for the said quarter provide a true and fair view of the affairs of the Company.



Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com


CIN : L24390MH1976PLC019380

- 4 The reconciliation between net profit for the quarter ended June 2015 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

	(Rs. in lakhs)
Net profit reported for June 2015 as per previous Indian GAAP	3,428.19
Add/(Less) : Adjustments	
Acturial loss on defined benefit plans reclassified to other comprehensive Income	11.84
Net gain arising on fair valuation of Investments	657.89
Net gain arising on fair Fair valuation of Forward Contracts	8.02
Others	13.73
Deferred Tax Impact on above Adjustments	(155.89)
Net Profit after Tax as per Ind AS	3,963.78

- 5 The Company has one reportable segment viz. Pharmaceuticals.
6 The figures for the previous period have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B.Mody

Chairman & Managing Director

Place : Mumbai

Date : August 26, 2016

